A takeover rumor regarding Akero Therapeutics (AKRO) was highlighted in Ben Harrington’s M&A-focused Betaville blog, contacts tell The Fly. Akero shares are up 93c, or 2%, to $55.21 in early Monday trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Akero Therapeutics Elects New Directors at Annual Meeting
- Buy Rating for Akero Therapeutics Driven by EFX’s Promising Position in MASH Treatment and Market Potential
- 3 Best Stocks to Buy Now, 5/27/2025, According to Top Analysts
- Akero Therapeutics price target raised to $64 from $63 at BofA
- Biotech Alert: Searches spiking for these stocks today